Oncopeptides
Biotech firm developing targeted therapies for hematological cancers.
ONCO | ST
Overview
Corporate Details
- ISIN(s):
- SE0009414576 (+4 more)
- LEI:
- 549300J9WWQ5CBYQ1M77
- Country:
- Sweden
- Address:
- Luntmakargatan 46, 111 37 Stockholm
- Website:
- https://www.oncopeptides.com/en
- Sector:
- Manufacturing
Description
Oncopeptides is a biotechnology company focused on the research, development, and commercialization of targeted therapies for difficult-to-treat cancers. The company concentrates on hematological diseases, with a primary focus on multiple myeloma. Its commercialized product is Pepaxti (melflufen), a peptide-drug conjugate for adult patients with relapsed or refractory multiple myeloma. Founded in 2000 based on research from leading cancer institutions, Oncopeptides leverages its proprietary technology platforms to advance a pipeline of innovative drug candidates. The company's research also includes the development of Natural Killer (NK) cell engagers to address unmet medical needs in oncology.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Type / Size | Actions | |
|---|---|---|---|---|---|
| 2024-04-17 14:10 |
Oncopeptides publishes prospectus relating to the rights issue
|
English | PDF • 76.7 KB | ||
| 2024-04-15 15:30 |
Bulletin from an Extraordinary General Meeting in Oncopeptides AB (publ)
|
English | PDF • 63.2 KB | ||
| 2024-04-15 15:30 |
Kommuniké från Extra Bolagsstämma i Oncopeptides AB (publ)
|
Swedish | PDF • 63.9 KB | ||
| 2024-04-08 07:35 |
Oncopeptides announces final terms for the fully guaranteed rights issue
|
English | PDF • 103.2 KB | ||
| 2024-04-08 07:35 |
Oncopeptides offentliggör slutliga villkor för den fullt garanterade företrädes…
|
Swedish | PDF • 104.5 KB | ||
| 2024-04-04 08:00 |
Oncopeptides releases first quarter 2024 sales
|
English | PDF • 71.6 KB | ||
| 2024-04-04 08:00 |
Oncopeptides offentliggör försäljning för första kvartalet 2024
|
Swedish | PDF • 77.6 KB | ||
| 2024-03-13 17:00 |
Extraordinary General Meeting in Oncopeptides AB (publ)
|
English | PDF • 111.6 KB | ||
| 2024-03-13 17:00 |
Extra bolagsstämma i Oncopeptides AB (publ)
|
Swedish | PDF • 114.8 KB | ||
| 2024-03-13 07:30 |
Oncopeptides genomför en fullt garanterad företrädesemission om cirka 300 miljo…
|
Swedish | PDF • 110.0 KB | ||
| 2024-03-13 07:30 |
Oncopeptides carries out a fully guaranteed rights issue of approximately SEK 3…
|
English | PDF • 109.0 KB | ||
| 2024-02-27 08:00 | Swedish | PDF • 570.6 KB | |||
| 2024-02-27 08:00 | English | PDF • 501.6 KB | |||
| 2024-02-23 12:49 |
Oncopeptides receives positive recommendation for Pepaxti by Spanish Pricing Au…
|
English | PDF • 71.9 KB | ||
| 2024-02-23 12:49 |
Oncopeptides får positiv rekommendation av Pepaxti från den spanska prismyndigh…
|
Swedish | PDF • 72.4 KB |
Automate Your Workflow. Get a real-time feed of all Oncopeptides filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Oncopeptides
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Oncopeptides via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-04-15 | David Augustsson | Other | Buy | 1,250 | 6,350.00 SEK |
| 2024-04-15 | David Augustsson | Other | Buy | 1,250 | 6,312.50 SEK |
| 2024-04-15 | David Augustsson | Other | Buy | 438 | 2,225.04 SEK |
| 2024-04-15 | David Augustsson | Other | Buy | 60 | 303.60 SEK |
| 2024-04-15 | David Augustsson | Other | Buy | 2 | 10.02 SEK |
| 2023-09-08 | David Augustsson | Other | Buy | 2,296 | 17,706.75 SEK |
| 2023-08-10 | David Augustsson | Other | Buy | 1,704 | 14,995.20 SEK |
| 2023-05-04 | Nicolaas Bakker | Other | Buy | 5,000 | 42,380.00 SEK |
| 2022-10-10 | Nicolaas Bakker | Other | Buy | 15,000 | 164,400.00 SEK |
| 2022-08-30 | Per Wold-Olsen | Other | Buy | 2,050 | 55,350.00 SEK |
Peer Companies
/other/Diamyd_Medical_AB_publ-logo.png){kind=logo}